According to the lawsuit, during the Class Period, defendants made materially false and misleading statements regarding Ardelyx’s future revenue and funding requirements, and the commercial success of a phosphorus inhibitor, XPHOZAH. Among other things, Ardelyx would apply to include XPHOZAH in the Transitional Drug Add-on Payment Adjustment program (“TDAPA”) when in fact, Ardelyx had not yet reached a firm decision concerning whether or not to apply to include XPHOZAH in TDAPA.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
